DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
QUICK SEARCH:   [advanced]


     

Drug Metabolism and Disposition Fast Forward
First published on July 9, 2007; DOI: 10.1124/dmd.107.016279

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.107.016279v1
35/10/1942    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zheng, Y.
Right arrow Articles by Lazarus, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zheng, Y.
Right arrow Articles by Lazarus, P.


Received for publication April 13, 2007.
Revised July 2, 2007.
Accepted for publication July 3, 2007.

ELIMINATION OF ANTI-ESTROGENIC EFFECTS OF ACTIVE TAMOXIFEN METABOLITES BY GLUCURONIDATION

Yan Zheng 1, Dongxiao Sun 1, Arun k Sharma 1, Gang Chen 1, Shantu Amin 1, Philip Lazarus 1*

1 Penn State University College of Medicine

* Address correspondence to: E-mail: plazarus{at}psu.edu

Abstract

TAM is a nonsteroidal anti-estrogen that has been commonly used for the prevention and treatment of estrogen receptor-positive breast cancer. TAM is extensively metabolized into several primary active metabolites including 4-OH-TAM and endoxifen. Glucuronidation is the major phase II metabolic pathway important in their excretion. While high anti-estrogenic activity has been reported for both 4-OH-TAM and endoxifen, studies examining the effect of glucuronide conjugation of these metabolites have not previously been performed. In the present study, the anti-estrogenic activities of glucuronidated TAM metabolites were determined by examining their effect on the induction of the estrogen-responsive PGR gene. E2-mediated PGR gene expression in MCF-7 cells was determined by real-time RT-PCR for each TAM metabolite isomer. E2 (1x10-10 M) induction of PGR mRNA was 6-fold after 12 h incubation; only unconjugated TAM metabolites inhibited this effect. A virtually identical dose-dependent inhibition of E2-induced PGR gene expression was found for both the trans and cis isomers of 4-OH-TAM and endoxifen, with maximal inhibition attained at 1 x10-6 M of TAM metabolite. The glucuronide conjugates of all 4-OH-TAM and endoxifen isomers exhibited no effect on E2-mediated induction of PGR expression at all concentrations of TAM metabolite examined in this study. These data indicate that isomers of both 4-OH-TAM and endoxifen exhibit roughly equipotent anti-estrogenic effects on E2-induced gene expression and that glucuronide conjugates of the same metabolites effectively negate this activity. This may has important implications in terms of both whole-body and target-tissue-specific glucuronidation pathways and individual response to TAM therapy and cancer prevention.


Key words: drug disposition, glucuronidation, phase II drug metabolism, UDP glucuronyltransferases


This article has been cited by other articles:


Home page
 Cancer Res.Home page
A. S. Blevins-Primeau, D. Sun, G. Chen, A. K. Sharma, C. J. Gallagher, S. Amin, and P. Lazarus
Functional Significance of UDP-Glucuronosyltransferase Variants in the Metabolism of Active Tamoxifen Metabolites
Cancer Res., March 1, 2009; 69(5): 1892 - 1900.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics.